This manuscript reviews the clinical trials with cytokines in solid tumors. Starting with Interleukin 2 alone or in association with other cytokines and chemotherapy, the reviews opens the prospects of future direction for the use of cytokines as adjuvant therapy, for vaccination or to inhibit the growth activity of certain cytokines.